Healthcare
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients
The new pill is also aimed at people who are doing well on a single-tablet regimen, including Biktarvy, and want to switch to a new treatment.
Company
GILD
Gilead
No market stories in the last 7 days. The latest coverage is below.
- 7-day mood
- —Not enough data
- Stories, 7 days
- 0
- Last 24 hours
- 0no baseline yet
- Sources
- 10in the latest 29
Mood and coverage · last 7 days
Market chart- Gilead · 6-hour average
- Hourly reading
- Stories per hour
No scored stories in the last 7 days.
View as table
| Day | Mood | Stories |
|---|---|---|
| Sat, Oct 10 | — | 0 |
| Fri, Oct 9 | — | 0 |
| Thu, Oct 8 | — | 0 |
| Wed, Oct 7 | — | 0 |
| Tue, Oct 6 | — | 0 |
| Mon, Oct 5 | — | 0 |
| Sun, Oct 4 | — | 0 |
| Sat, Oct 3 | — | 0 |
Latest on Gilead
Newest firstHealthcare
Best Pharmaceutical Stocks To Consider - June 25th
Eli Lilly and Company, AbbVie, Abbott Laboratories, Pfizer, McKesson, Gilead Sciences, and Ascendis Pharma A/S are the seven Pharmaceutical stocks to watch tod…
Markets
Rep. Josh Gottheimer Purchases Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Representative Josh Gottheimer (Democratic-New Jersey) recently bought shares of Gilead Sciences, Inc. (NASDAQ:GILD). In a filing disclosed on February 26th, t…
Healthcare
Gilead shows its belief in its partner's cancer treatment with a $7.8 billion buyout
Arcellx's stock is heading toward a record after the $7.8 billion deal to be acquired by Gilead.
Healthcare
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion
Gilead Sciences said on Monday it will buy cancer therapy partner Arcellx for an implied equity value of $7.8 billion.
Healthcare
Trump announces lower drug price deals with 9 pharmaceutical companies
U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the U.S. Amgen, Bristol Myers Sq…
Markets
Upcoming Dividend Run For GILD?
This morning a "Potential Dividend Run Alert" went out for Gilead Sciences Inc (NASD: GILD), at our DividendChannel.com Dividend Alerts service (a free email a…
Healthcare
EU Approves Gilead's Twice-Yearly Lenacapavir For HIV Prevention
(RTTNews) - Gilead Sciences, Inc. (GILD) Tuesday said that the European Commission has granted marketing authorization for lenacapavir for pre-exposure prophyl…
Markets
Why Gilead Sciences is a Top 25 Dividend Giant (GILD)
Gilead Sciences Inc (Symbol: GILD) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a whopping $27.06B worth of stock held by ETFs, and above…
Healthcare
Friday Sector Leaders: Healthcare, Financial
The best performing sector as of midday Friday is the Healthcare sector, up 1.0%. Within that group, Gilead Sciences Inc (Symbol: GILD) and STERIS plc (Symbol:…
Consumer
Stocks making the biggest moves midday: Gilead Sciences, Monster Beverage, Trade Desk, MP Materials, Sweetgreen and more
These are the stocks posting the largest moves in midday trading.
Healthcare
Validea Detailed Fundamental Analysis - GILD
Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Twin Momentum Inve…
Healthcare
Friday Sector Laggards: Healthcare, Materials
In afternoon trading on Friday, Healthcare stocks are the worst performing sector, showing a 1.3% loss. Within that group, Gilead Sciences Inc (Symbol: GILD) a…
Healthcare
FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention
GILD wins FDA approval for Yeztugo, the first and only twice-yearly injectable PrEP for HIV prevention in the United States.
Healthcare
FDA approves HIV prevention drug taken as twice-yearly injection
Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained HIV negative.
Healthcare
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
The launch of the injection faces potential threats, including the Trump administration's proposed cuts to federal funding for HIV prevention efforts.
Markets
Gilead Sciences a Top Socially Responsible Dividend Stock With 2.9% Yield (GILD)
Gilead Sciences Inc (Symbol: GILD) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''Divide…
Markets
What Are Wall Street Analysts' Target Price for Gilead Sciences Stock?
Gilead Sciences has considerably outpaced the broader market over the past year, and Wall Street analysts maintain a moderately optimistic outlook on the stock…
Markets
Here's What to Expect From Gilead Sciences' Next Earnings Report
Gilead Sciences is expected to announce its fiscal first-quarter earnings this month, and analysts forecast a robust triple-digit in its earnings.
Healthcare
'Handmaid's Tale' Producer Calls Series A 'Symbol Of Resistance' Against Trump
One of the executive producers of "The Handmaid's Tale,†a dystopian drama based on the book of the same name by Margaret Atwood, referenced how the show is…
Markets
Stocks making the biggest moves midday: Boeing, Nvidia, Autodesk, Gilead Sciences and more
These are the stocks posting the largest moves in midday trading.
Markets
GILD Factor-Based Stock Analysis
Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Twin Momentum Inve…
Markets
Stocks making the biggest moves premarket: General Mills, Gilead Sciences, Tesla and more
These are the stocks posting the largest moves in premarket trading.
Healthcare
Gilead's Phase 1 Data Shows Promise For Once-Yearly Lenacapavir In HIV Prevention
(RTTNews) - Gilead Sciences Inc. (GILD) announced that phase 1 study data showed two different formulations of once-yearly lenacapavir, administered via intram…
Markets
Buy Gilead Sciences (GILD) Stock at 52-Week Highs?
Medical pioneer Gilead Sciences (GILD) has seen its stock etch out new 52-week highs as the broader market pulled back sharply in recent weeks.
Markets
How Is Gilead Sciences' Stock Performance Compared to Other Pharmaceutical Stocks?
As Gilead Sciences has outperformed its industry peers recently, Wall Street analysts maintain a moderately optimistic outlook on the stock's prospects.
Healthcare
Gilead Sciences: FDA To Review NDA Submissions For Lenacapavir - Quick Facts
(RTTNews) - Gilead Sciences (GILD) announced that the FDA has accepted its New Drug Application submissions for lenacapavir-the twice-yearly injectable HIV-1 c…
Markets
Gilead Sciences (GILD) Shares Cross 3% Yield Mark
Looking at the universe of stocks we cover at Dividend Channel, in trading on Friday, shares of Gilead Sciences Inc (Symbol: GILD) were yielding above the 3% m…